skip to main content
UK Health Security Agency

MCF7/182R-7

MCF7/182R-7

Catalogue No.

16022502

Cell Line Name

MCF7/182R-7

Cell Line Description

The MCF7/182R-7 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal anti-oestrogen ICI 182,780 (Fulvestrant) at 100 nM concentration, Lykkesfeldt et al. (1995). The MCF7/182R-7 cells can be maintained continuously in growth medium with 100 nM Fulvestrant.

Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant.

Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.

General Info

Species

Human

Unique to ECACC

Yes

Also Known As

MCF7/182R-7; 182R-7, MCF-7/182R-7

Release Conditions

Restricted - all organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Tissue of Origin

Breast

Morphology

Polygonal epithelium

DNA profile (STR Profile)

DNA Profile (STR Analysis)
Amelogenin: X, X
CSF1PO: 10, 10
D3S1358: 16, 16
D5S818: 11, 12
D7S820: 9, 9
D8S1179: 10, 14
D13S317: 11, 11
D16S539: 11, 12
D21S11: 30, 30
FGA: 23, 25
Penta D: 12, 12
Penta E: 7, 12
TH01: 6. 6
TPOX: 9, 12
vWA:14, 15

Applications

Treatment with the steroidal anti-oestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. This cell line will provide a model for the clarification of molecular changes associated with the development of resistant growth after targeted treatments.

Disease

Pleural Effusion of a Ductal Carcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Split sub-confluent cultures at 70-80% confluency. Subculture cells using 0.05% trypsin/EDTA solution and soya bean trypsin inhibitor or TrypLE Express™ (1X), without phenol red, and wash with phosphate- buffered saline (PBS).

Pellet cells by centrifugation at 100 x g and re-suspend in growth medium. Initiate the culture seeding at 2-4x104 cells/cm2. Incubate cultures in 5% CO2 at 37°C. Recommend media changes every 2-3 days.

Cells can be cryopreserved in cell line conditioned medium (45%) and fresh serum free-medium (45%) with 10% dimethyl sulphoxide (DMSO) or 90% FBS and 10% DMSO. It is recommended that upon resuscitation the cells are washed in PBS or serum-free medium, pelleted by centrifugation and re-suspended in growth medium prior to initiation.

Culture Medium

Phenol red free DMEM/F12 (1:1) supplemented with 1% FBS, 2.5 mM Glutamax and 6 ng/ml insulin.

Supplemented with 100 nM Fulvestrant to maintain resistance.

Growth Mode

Adherent

Additional Info

Depositor

Cancertools (formally Ximbio) 2 Redman Place, London E20. 1JQ Tel +44 (0) 20 3469 6449 www.cancertools.org Originator: Anne Lykkesfeldt, Breast Cancer Research Department, Danish Cancer Society, Copenhagen

Country of Origin

Denmark

GMO Status

Not Applicable

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Thrane et al. 2014. Oncogene. PMID: 25362855.
Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-75. PMID: 18409071.
Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041.

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Bibliography

Christensen et al. 2004. Breast Cancer Res Treat. 85(1):53-63. PMID: 15039597.
Larsen et al. 1997. Int J Cancer. 72(6):1129-36. PMID: 9378550.
Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: MCF7/182R-7 (ECACC 16022502).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.

 

ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.